Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

No Publisher
213 Pages - GMD18357
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 3, 9, 10, 1, 2, 50 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: AM-Pharma announces two presentations at the 27th International Conference on Advances in Critical Care Nephrology
Feb 15, 2022: Haisco's announcement on obtaining the "Notice of Acceptance" for clinical trial application of innovative drug HSK36212 capsules
Feb 03, 2022: Arch Scientists publish data on the mechanism of action and efficacy of lead drug candidate LSALT peptide in the prevention of acute kidney injury
Dec 09, 2021: Angion and Vifor Pharma report topline results from phase 2 GUARD trial of ANG-3777 in cardiac surgery-associated acute kidney injury
Oct 14, 2021: XORTX announces results from Mount Sinai’s COVID-19 clinical study
Aug 05, 2021: Arch Biopartners provides update on phase II trial for LSALT peptide
Jul 01, 2021: AM-Pharma enrolls first patient in Japan for ongoing phase III SA-AKI pivotal REVIVAL trial
Jun 28, 2021: ILIAS Biologics demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury
Jun 17, 2021: KBI Biopharma enters commercial manufacturing agreement with AM-Pharma to prepare for the commercial launch of lead program in acute kidney disease
Jun 10, 2021: Arch Biopartners files new patent application for novel antibody candidates targeting DPEP-1 mediated organ inflammation
May 03, 2021: Lyfaquin, a resuscitative agent marketed in India, restores renal blood flow and protects tissue damage after hemorrhagic shock-induced acute kidney injury (AKI)
Apr 29, 2021: Angion and Vifor Pharma announce completion of enrollment in phase 2 study of ANG-3777 for cardiac-surgery associated acute kidney injury
Apr 22, 2021: Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST for the prevention of acute kidney injury after myocardial infarction
Mar 30, 2021: Turkish Ministry of Health approves increase in patient recruitment into the phase II trial for LSALT peptide
Mar 17, 2021: Arch Biopartners secures approval to amend LSALT Peptide trial protocols
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Amniotics AB, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Anagenics Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angiotensin Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Arch Biopartners Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Ashvattha Therapeutics LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Axolo Pharma Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Balmes Transplantation SAS, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bessor Pharma LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by CFM Pharma Holding BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Chaperone Pharma BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Claritas Pharmaceuticals Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Curigin Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cypralis Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec SE, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Faron Pharmaceuticals Oy, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Goldilocks Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Guard Therapeutics International AB, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by HemaFlo Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hybridize Pharma BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by iCELL Biotechnology Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ILIAS Biologics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Johnson & Johnson, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kantum Pharma Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Klotho Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Liminal BioSciences Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by LTT Bio-Pharma Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Meridigen Biotech Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Metro International Biotech LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mission Therapeutics Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitobridge Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotherapeutix LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeoProgen Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nephraegis Therapeutics, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orgenesis Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Paranta Biosciences Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Pharmazz Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Pharmicell Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Pharming Group NV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Praetego Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Q BioMed Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Radikal Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rediscovery Life Sciences, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Renibus Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rui Nuo Medical Technology (Shanghai) Co Ltd, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Sentien Biotechnologies Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Sidereal Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Silver Creek Pharmaceuticals Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Slate Bio Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Sulfateq BV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by TES Pharma SRL, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by TheraSource LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Theratome Bio Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Unicycive Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Unicyte AG, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Valo Health LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Vasculonics LLC, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Vasomune Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by vasopharm GmbH, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Vivoryon Therapeutics NV, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by XORTX Therapeutics Inc, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, 2022
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, 2022 (Contd..1)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, 2022 (Contd..2)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838